Quoin Pharmaceuticals, Ltd. (QNRX)
QNRXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.70
-0.1600 (-4.15%) today
Closed, Nov 13, 4:00 PM ET
- Market cap
- $17.78m
- P/E
- –
- EPS, last 4 quarters
- $-19.44
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.25 to $23.50
- Average volume
- –
- Previous close
- $3.86
Analysts
5 coveringStrong Buy5 buy, 0 hold, 0 sell
Targets a year out average $21.40, +478.4% from here
Earnings
next estimate $-1.90Next report
Dec 2025
-130.5%
Mar 2026
+1.7%
Jun 2026
-3.8%
Sep 2026
+48.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$4.52m | -$5.13m | -$5.47m | -$4.92m |
| Net income | -$4.35m | -$5.00m | -$5.37m | -$4.87m |
News
8 latest- Quoin Pharmaceuticals, Ltd. Reports Third Quarter 2026 Financial ResultsFintel · Nov 6, 2026
- Quoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin Disorder RTTNews · Oct 14, 2026
- Quoin Gets FDA Fast Track Designation For QRX003 In Peeling Skin Syndrome RTTNews · Sep 23, 2026
- FDA Grants Rare Pediatric Disease Designation To Quoin's QRX003 For PSS RTTNews · Sep 8, 2026
- Quoin Pharma Surges 45% In Pre-Market On Positive QRX003 Data And $50M Private Placement RTTNews · Aug 28, 2026
- Quoin Q2 Loss Widens; Gets FDA's Conditional Nod For QYLEKI Brand Name For QRX003 RTTNews · Aug 14, 2026
- Pre-Market Earnings Report for August 14, 2026 : USAS, SGML, OTLK, STRR, PAVM, LFWD, CMCT, QNRX, ACXPNASDAQ.com · Aug 13, 2026
- Quoin Receives FDA IND Clearance To Initiate Phase 2 Study Of QRX003 In Peeling Skin Syndrome RTTNews · Jul 9, 2026
The company
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin's innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- quoinpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.